Molecular mechanism of an antagonistic antibody against glucose-dependent insulinotropic polypeptide receptor
Xiaoshan Min(Amgen (United States)), Zhulun Wang(Amgen (United States)), Murielle M. Véniant(Amgen (United States)), Ben C. Chung(Amgen (United States)), Ching-Shin Huang(Pfizer (United States)), Christina M. Abbott(Amgen (United States)), Jie Yang(Scripps Institution of Oceanography), Joanne Lin(Amgen (United States)), Caroline Gundel(Amgen (United States)), Shi‐Yuan Meng(Amgen (United States)), David J. Lloyd(Genomics Institute of the Novartis Research Foundation), D.L. Bates(Amgen (United States)), Junming Yie(Amgen (United States)), Jinghong Wang(Amgen (United States)), Qing Chen(Kunming Medical University), Haoda Xu(Amgen (United States)), Liying Deng(Amgen (United States)), Stephen Thibault(Amgen (United States))
Cited by 8
Related Papers
Molecular basis for the loss-of-function effects of the Alzheimer's disease–associated R47H variant of the immune receptor TREM2
|Journal of Biological Chemistry|2018|148
Obesity, hyperphagia and increased metabolic efficiency in Pc1 mutant mice
|Human Molecular Genetics|2006|139
Chronic glucose-dependent insulinotropic polypeptide receptor (GIPR) agonism desensitizes adipocyte GIPR activity mimicking functional GIPR antagonism
|Nature Communications|2020|134
Cryo-EM structures of NPC1L1 reveal mechanisms of cholesterol transport and ezetimibe inhibition
|Science Advances|2020|95